EUCTR2021-000041-40-NL进行中（未招募）1 期
A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action - Microdosing and Parkinson’s disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-At least 18 years of age
- •-Being diagnosed with Parkinson’s disease, and able to provide evidence for this (e.g., letter from a medical doctor or DaT-scan)
- •-Underwent a DaT scan as part of the diagnostic process
- •-Being able to provide details about the duration of the disease or provide medical records
- •-Free from conventional Parkinson medication (i.e., Levodopa, dopamine agonist, amantadine, adenosine a2a antagonist, COMT inhibitors, anticholinergic drugs, MAO inhibitors)
- •-The participant is, in the opinion of the investigator, generally healthy based on assessment of medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests
- •-A resting pulse and heart rate (as read on the ECG) =51 bpm and =100 bpm. For participants in good physical condition, the lower limit is =45 bpm.
- •-A resting systolic blood pressure =91 mmHg and =140 mmHg and a resting diastolic blood pressure =51 mmHg and =90 mmHg.
- •-Clinical laboratory test values within clinical reference ranges at screening. Borderline values may be accepted if they are, in the opinion of the investigator, clinically insignificant.
- •-Normal binocular visual acuity, corrected or uncorrected
- •-Absence of any major medical, endocrine and neurological condition (apart from Parkinson’s disease), as determined by the medical history, medical examination, electrocardiogram and laboratory analyses (haematology, clinical chemistry, urinalysis, serology).
- •-Normal weight, body mass index (weight/height2) between 19,5 and 28 kg/m2
- •-Being able to communicate in Dutch or English
- •-Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •-Previous experience of serious side effects to psychedelic drugs (anxiety or panic attacks)
- •-Use of conventional Parkinson’s disease medication (i.e., Levodopa, dopamine agonist, amantadine, adenosine a2a antagonist, COMT inhibitors, anticholinergic drugs, MAO inhibitors)
- •-Use of other psychiatric medication
- •-History of drug addiction (determined by the medical questionnaire, drug questionnaire and medical examination)
- •-Depression or dementia
- •-Excessive alcohol consumption (>20 units a week)
- •-Excessive smoking (>20 cigarettes a week)
- •-Current or history of psychiatric disorder (determined by the medical questionnaire and medical examination)
- •-Hypertension (diastolic >90; systolic >140)
- •-Liver dysfunction
- •-History of cardiac dysfunctions (arrhythmia, ischemic heart disease, etc)
- •-Pregnancy or lactation
研究者
相似试验
撤回
2 期
A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson*s disease and to understand its mechanism of actioParkinson's disease10029305NL-OMON52045niversiteit Maastricht34
进行中（未招募）
1 期
A Study to Investigate the Effects of NPC-06 on the Pharmacokinetics of Amenamevir.JPRN-jRCT2031220593Takahashi Morito20
进行中（未招募）
1 期
A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to healthy adult participantsPlaque PsoriasisCTIS2023-509030-19-00Janssen Cilag International36
已完成
不适用
Effects of Sokatin® on emotional memory and set shiftingISRCTN70153100Dr. Willmar Schwabe GmbH & Co. KG (Germany)48
尚未招募
4 期
A randomized study to compare the effect of low-dose Ketamine versus Fentanyl on the hemodynamic response to laryngoscopy and endotracheal intubation.CTRI/2024/07/071287SMS Medical College